Hypothesis

Rapamycin extends lifespan not only by suppressing mTORC1 but also by triggering a mild, reversible mitochondrial uncoupling that phenocopies cold‑induced thermogenesis. This uncoupling raises NAD⁺/NADH ratios, activates SIRT1‑dependent deacetylation of PGC‑1α, and drives FGF21 secretion from adipose tissue, which feeds back to further inhibit mTORC1 systemically. When rapamycin is withdrawn, the uncoupling subsides, NAD⁺ levels fall, SIRT1 activity drops, and the longevity program collapses, explaining the transient nature of its benefits.

Mechanistic Rationale

1. mTORC1 inhibition raises cellular AMP/ATP ratios, which can activate AMPK. AMPK phosphorylates and activates mitochondrial uncoupling proteins (UCPs) such as UCP2 in liver and UCP3 in skeletal muscle, lowering membrane potential and increasing proton leak.
2. Mild uncoupling elevates NAD⁺ regeneration via increased TCA cycle flux to compensate for ATP loss, boosting the NAD⁺/NADH ratio.
3. Higher NAD⁺ fuels SIRT1 activity, leading to deacetylation and activation of PGC‑1α, a master regulator of mitochondrial biogenesis and fatty‑acid oxidation.
4. PGC‑1α drives expression of FGF21 in adipose tissue and liver; circulating FGF21 acts as an endocrine signal that suppresses mTORC1 in multiple tissues via activation of the ERK1/2‑PP2A axis.
5. The loop is self‑reinforcing: FGF21 further enhances AMPK activity and UCP expression, sustaining the low‑energy state as long as rapamycin is present to keep mTORC1 dampened.

Predictions

• Rapamycin‑treated mice will show increased basal oxygen consumption rate (OCR) and proton leak in isolated hepatocytes and myocytes compared with controls, an effect reversible after drug washout.
• Genetic deletion of Ucp2 in liver or Ucp3 in muscle will blunt the rise in NAD⁺/NADH, reduce SIRT1 target deacetylation, and abolish rapamycin‑mediated lifespan extension despite unchanged mTORC1 phosphorylation.
• Exogenous FGF21 will mimic rapamycin’s effect on mTORC1 signaling and lifespan in wild‑type mice, whereas FGF21‑neutralizing antibodies will attenuate rapamycin benefits.
• Circadian profiling will reveal that the uncoupling‑induced NAD⁺ surge peaks during the early subjective night, aligning with reported time‑of‑day sensitivity of CR‑mediated mTOR inhibition.

Experimental Design

1. Metabolic phenotyping: Use Seahorse XF analyzers on primary hepatocytes from rapamycin‑treated (4 weeks) and withdrawn mice; measure basal OCR, ATP‑linked respiration, and proton leak.
2. Genetic intervention: Cross Ucp2^fl/fl or Ucp3^fl/fl mice with Alb‑Cre or HSA‑Cre lines; treat cohorts with rapamycin (14 ppm diet) and monitor survival.
3. Hormonal assays: Quantify plasma NAD⁺, NADH, SIRT1 activity (acetyl‑p53 levels), PGC‑1α acetylation, and FGF21 via ELISA at multiple Zeitgeber times.
4. Rescue experiments: Administer recombinant FGF21 (1 mg/kg i.p. every other day) to rapamycin‑withdrawn mice and assess whether survival curves are restored.
5. Circadian sampling: Collect tissues every 4 h over 24 h to map NAD⁺/SIRT1/UCP expression rhythms.

Falsifiability

If rapamycin extends lifespan without detectable increases in mitochondrial proton leak, NAD⁺/NADH shifts, or FGF21 elevation, or if Ucp2/Ucp3 loss fails to shorten lifespan despite continued mTORC1 suppression, the hypothesis would be falsified. Conversely, confirmation of the predicted metabolic and endocrine changes, and their dependence on UCPs, would support the model that rapamycin’s longevity signal is a hormetic mimic of cold‑stress‑induced mitochondrial uncoupling rather than a pure growth‑signal blockade.